Methadone is a Non-Competitive Antagonist at the alpha 4 beta 2 and alpha 3*Nicotinic Acetylcholine Receptors and an Agonist at the alpha 7 Nicotinic Acetylcholine Receptor

摘要

Nicotine-methadone interactions have been studied in human beings and in various experimental settings regarding addiction, reward and pain. Most methadone maintenance treatment patients are smokers, and methadone administration has been shown to increase cigarette smoking. Previous in vitro studies have shown that methadone is a non-competitive antagonist at rat 34 nicotinic acetylcholine receptors (nAChR) and an agonist at human 7 nAChRs. In this study, we used cell lines expressing human 42, 7 and 3* nAChRs to compare the interactions of methadone at the various human nAChRs under the same experimental conditions. A [H-3]epibatidine displacement assay was used to determine whether methadone binds to the nicotinic receptors, and Rb-86(+) efflux and changes in intracellular calcium [Ca2+](i) were used to assess changes in the functional activity of the receptors. Methadone displaced [H-3]epibatidine from nicotinic agonist-binding sites in SH-EP1-h7 and SH-SY5Y cells, but not in SH-EP1-h42 cells. The K-i values for methadone were 6.3M in SH-EP1-h7 cells and 19.4M and 1008M in SH-SY5Y cells. Methadone increased [Ca2+](i) in all cell lines in a concentration-dependent manner, and in SH-EP1-h7 cells, the effect was more pronounced than the effect of nicotine treatment. In SH-EP1-h42 cells, the effect of methadone was negligible compared to that of nicotine. Methadone pre-treatment abolished the nicotine-induced response in [Ca2+](i) in all cell lines expressing nAChRs. In SH-EP1-h42 and SH-SY5Y cells, methadone had no effect on the Rb-86(+) efflux, but it antagonized the nicotine-induced Rb-86(+) ion efflux in a non-competitive manner. These results suggest that methadone is an agonist at human 7 nAChRs and a non-competitive antagonist at human 42 and 3* nAChRs. This study adds further support to the previous findings that opioids interact with nAChRs, which may underlie their frequent co-administration in human beings and might be of interest to the field of drug discovery.